TissueGen Founder and CSO Dr. Kevin Nelson to Present “Latest Advancement in Extrusion Technology for Drug Delivery Applications” Session at the IFAI Expo

27 Sep TissueGen Founder and CSO Dr. Kevin Nelson to Present “Latest Advancement in Extrusion Technology for Drug Delivery Applications” Session at the IFAI Expo

WHO: TissueGen® Inc., developer of ELUTE® fiber, enables controlled sustained delivery of sensitive pharmaceuticals and biologics from biodegradable fibers for advanced drug delivery, nerve regeneration, and tissue engineering. TissueGen works with leading pharmaceutical, therapeutic and medical device companies to develop fiber and textile medical devices for use in drug delivery applications such as small diameter vascular grafts and stents, tissue and nerve regeneration, orthopedic devices and sutures.

WHAT: Dr. Kevin Nelson,  TissueGen, Inc.’s Founder and CSO, will be presenting on the latest advancements in extrusion technology which are enabling the advanced drug delivery at IFAI Expo 2018.

During the session, Dr. Nelson will discuss how the medical device industry has undergone significant evolution over the past few decades—and drug delivery is moving to the forefront.  With the rapid adoption of drug-eluting stents, the medical industry has recognized the value that drug delivery coupled with a medical device can bring to patient care.  Enabling the controlled-release of pharmaceutical and biological agents applied topically or within the body directly to the internal sites where they are needed most has the potential to revolutionize spinal cord repair, nerve generation, tumor remediation and many more applications.

To set up a meeting, please contact Christopher Knowles at cknowles@tissuegen.com or 1.214.351.1922.

WHEN: Dr. Nelson’s presentation will take place on October 15th at 11:10 am CST. The IFAI Expo will run from October 15-18, 2018.

Kay Bailey Hutchison Convention Center
650 S Griffin Street
Dallas, Texas 75202

To schedule a briefing, please contact Sage Morander at sage.morander@svmpr.com or 1.401.490.9700.

About TissueGen
TissueGen® Inc. is the developer of ELUTE® fiber, a groundbreaking biodegradable fiber format for advanced drug delivery, nerve regeneration and tissue engineering. TissueGen has extensive experience in extruding biodegradable polymer fibers with broad drug delivery capabilities. ELUTE fiber can directly replace standard fibers used in biodegradable textiles currently on the market and provide significantly improved clinical outcomes by delivering therapeutic agents directly at the site of the implant. By delivering drugs and growth factors at the site of implantation, ELUTE fiber enables medical devices to guide the body’s healing and regenerative processes. For more information, please visit www.tissuegen.com.

# # #

For more information contact:

Sage Morander
SVM Public Relations

No Comments

Sorry, the comment form is closed at this time.